BioRem Inc.

BioRem Inc.

BIRMF
BioRem Inc.US flagOther OTC
2.17
USD
-0.03
- -
35.23MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.51
0.82
1.24
1.03
0.59
0.63
0.53
0.63
0.68
1.86
1.61
2.37
2.64
2.73
Basic EPS, GAAP
0.06
-0.13
0.12
0.04
0.04
0.12
-0.03
0.05
0.04
0.1
0.14
0.19
0.3
0.31
Free Cash Flow per Basic Share
0.05
-0.04
0.16
-0.04
0.03
-0.01
0.06
0.08
0.1
0.08
- -
0.21
0.45
0.08
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-1.12
-0.22
-0.06
-0.01
0.13
0.24
0.21
0.26
-0.02
0.05
0.2
0.4
0.69
0.69
Tangible Book Value per Share
0.05
-0.02
0.14
0.16
0.19
0.33
0.3
0.35
0.05
0.29
0.43
0.67
0.93
0.94
Basic Weighted Avg Shares
13
13
14
15
38
39
39
39
36
15
16
16
16
16
Sales/Revenue/Turnover
20
11
17
16
23
24
21
24
24
29
25
37
42
44
Operating Margin (%)
6.32
-11.95
12.57
4.23
7.35
5.03
-6.3
10.51
9.53
9.15
12.26
11.74
15.52
15.05
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
1
-2
2
1
2
5
-1
2
1
2
2
3
5
5
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
21.92
36.23
32.32
21.86
26.63
23.89
23.96
Profit Margin (%)
3.66
-16.12
10
3.44
6.78
19.17
-6.31
8.57
5.3
5.59
8.66
8.13
11.37
11.21
Working Capital
- -
1
2
2
7
10
9
10
3
5
6
10
14
15
LT Debt
- -
1
- -
- -
- -
- -
- -
1
4
3
3
3
2
2
Total Equity
1
- -
2
2
7
13
12
14
2
5
7
11
15
15
Return on Invested Capital (%)
30.65
- -
52.51
14.3
27.89
- -
- -
16.23
14.43
20.79
22.71
24.59
29.64
30.06
Return on Capital (%)
-11.57
- -
159.17
41.07
45.33
- -
- -
22.08
16.62
34.29
37.32
37.18
41.56
43.13
Return on Common Equity (%)
- -
- -
- -
- -
- -
65.73
-14.85
22.82
- -
- -
111.93
64.73
55.42
56.53

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1
1
1
LT Borrowings
1
1
1
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
16
16
16
Market Capitalization
33
46
39

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
25
31
29
Cash, Cash Equivalents & STI
8
12
10
Accounts Receivable, Net
9
12
9
Inventories
2
1
2
Total Current Liabilities
13
16
14
Payables & Accruals
5
11
7
ST Debt
1
1
1
Deferred Revenue
7
5
6

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
50.11%
38.38%
40.48%
Free Cash Flow
-703.3%
-1,080.19%
119.46%
Net Income, GAAP
4.81%
23.89%
58.25%
Sales/Revenue/Turnover
11.43%
13.48%
13.19%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6
7
15
9
37
2025
5
9
11
17
42
2026
7
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.02
0.14
- -
0.19
2025
- -
0.05
0.07
- -
0.3
2026
0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Derek S. Webb
Full Time Employees
34
Sector
Industrials
Industry
Industrial - Pollution & Treatment Controls
Address
7496 Wellington Road 34 Puslinch ON Canada N0B 2J0
IPO Date
Dec 31, 2010
Website
biorem.biz
Business
BioRem Inc., an innovative clean technology company, specializes in the engineering, manufacturing, distribution, and sale of advanced air pollution control systems designed to neutralize odors, volatile organic compounds (VOCs), and hazardous air pollutants (HAPs). The company provides an array of solutions, including biofilters for managing odors, hydrogen sulfide, VOCs, and HAPs, alongside biotrickling filters tailored for applications involving elevated levels of hydrogen sulfide or other water-soluble VOCs. Their comprehensive offerings also feature multi-stage systems for municipal and urban wastewater treatment odor removal, biogas desulfurization technologies, dry scrubber adsorption systems, and specialized cannabis odor abatement solutions. Beyond equipment, BioRem delivers biological process and testing services, media sampling and analysis, system evaluations and inspections, and crucial media replacements and spare parts. The firm operates globally, maintaining a significant presence across Canada, the United States, China, and various international markets, with over 2,000 installations in 23 countries. Established in 1990, BioRem Inc. maintains its primary operational base in Puslinch, Canada. The company has demonstrated recent growth through substantial order backlogs, reaching approximately $71 million as of Q3 2025.

Company News

APIChatGPT
  • BioRem (CVE:BRM) Trading Down 2.4% – Time to Sell?

  • BIOREM Reports Strong First Quarter Financial Results and Continued Growth in Order Backlog